Travere Therapeutics' FILSPARI Recognized in Updated IgA Nephropathy Treatment Guidelines

Advancements in IgA Nephropathy Treatment Guidelines Highlight FILSPARI’s Role

Travere Therapeutics, Inc. and CSL Vifor have recently endorsed the updated 2025 clinical practice guidelines issued by Kidney Disease: Improving Global Outcomes (KDIGO) for managing IgA Nephropathy (IgAN). This latest iteration of clinical guidelines brings a renewed focus on enhancing patient care by establishing clear diagnostic criteria and treatment goals. A significant emphasis is placed on achieving remission of proteinuria, with targets set at less than 0.5 grams per day, and ideally under 0.3 grams per day, alongside strategies to slow the decline of estimated glomerular filtration rate (eGFR). This comprehensive approach aims to improve long-term kidney outcomes for patients suffering from this challenging condition.

Central to the updated guidelines is the recommendation of FILSPARI® (sparsentan), a Dual Endothelin Angiotensin Receptor Antagonist (DEARA), as a potential first-line treatment for IgAN-related nephron loss. This marks a notable shift from the traditional reliance on Renin-Angiotensin System inhibitors (RASi), which have long been the standard treatment approach. Clinical trials, particularly the PROTECT trial, underscore FILSPARI’s efficacy, as it involves a larger patient cohort than all previous RASi trials combined. This robust evidence establishes FILSPARI not only as a viable alternative but as a preferred option for clinicians aiming to optimize treatment for their patients.

The endorsement of these new guidelines is welcomed by experts in the field, including Prof. Dr. med. Jürgen Floege from RWTH Aachen University Hospital, who notes that the updated guidance represents a significant step forward for the IgAN community. It provides essential clarity for treatment decisions, ultimately aimed at improving patient outcomes. Dr. Achim Obergfell, Global Medical Lead at Travere, emphasizes the inclusion of FILSPARI in these recommendations as a validation of its favorable benefit-risk profile. The drug’s effectiveness in reducing proteinuria and slowing kidney function decline, coupled with its general tolerance, positions it as a crucial element in the evolving landscape of IgAN treatment.

In addition to its role in advancing treatment protocols, the inclusion of FILSPARI in the KDIGO guidelines reflects a collaborative effort to enhance the support available to clinicians and patients. By focusing on the complexities of IgAN management, these updated recommendations aim to streamline care and improve overall patient experiences. The ongoing commitment from Travere Therapeutics to innovate in this space demonstrates its dedication to addressing unmet medical needs in chronic kidney disease.